Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: A meta-analysis

Clinical and Experimental Rheumatology

Volumn 32, Issue 1, 2014, Pages 11-21

  Sun, Jianhong ^a   Zhang, Yuhui ^a   Liu, Lei ^a   Liu, Gang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Anti cyclic citrullinated peptide antibody; Meta analysis; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; HUMANS; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RHEUMATOID FACTOR;

EID: 84894024841     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. KLARESKOG L, CATRINA AI, PAGET S: Rheumatoid arthritis. Lancet 2009; 373: 659-72.
2. MYASOEDOVA E, DAVIS JM, 3rd, CROWSON CS et al.: Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010; 12: 379-85.
3. LAWRENCE RC, HELMICK CG, ARNETT FC et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-99.
4. KIELY PD, BROWN AK, EDWARDS CJ, et al.: Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology 2009; 48: 765-72.
5. HUIZINGA TW, MACHOLD KP, BREEDVELD FC, et al.: Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002; 46: 1155-9.
6. LORENZO M: Rheumatoid arthritis. Foot and Ankle Clinics 2007; 12: 525-37, vii.
7. ARNETT FC ES, BLOCH DA, MCSHANE DJ, FRIES JF, COOPER NS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
8. van der LINDEN MP, KNEVEL R, HUIZINGA TW, et al.: Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 2011; 63: 37-42.
9. DAVATCHI F, ABARI IS, SOROOSH S, et al.: Performance of the 2010 Rheumatoid Arthritis Classification Criteria. Int J Rheum Dis 2012; 15: 455-61.
10. VONKEMAN HE, van de LAAR MA: The new European League Against Rheumatism/American College of Rheumatology diagnostic criteria for rheumatoid arthritis: how are they performing? Curr Opin Rheumatol 2013; 25: 354-9.
11. KAY J, UPCHURCH KS: ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 2012; 51 (Suppl. 6): vi5-9
12. AGGARWAL R, LIAO K, NAIR R, et al.: Anticitrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 2009; 61: 1472-83.
13. SCHELLEKENS GA, VISSER H, de JONG BA, et al.: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-63.
14. ZENDMAN AJ, van VENROOIJ WJ, PRUIJN GJ: Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology 2006; 45: 20-5.
15. RIEDEMANN JP, MUNOZ S, KAVANAUGH A: The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis--a systematic review. Clin Exp Rheumatol 2005; 23: S69-76.
16. NISHIMURA K, SUGIYAMA D, KOGATA Y, et al.: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808.
17. KHAN AH, JAFRI L, HUSSAIN MA, et al.: Diagnostic utility of anti-citrullinated protein antibody and its comparison with rheumatoid factor in rheumatoid arthritis. J Coll Physicians Surg Pak 2012; 22: 711-5.
18. VALLBRACHT I, HELMKE K: Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Autoimmunity Rev 2005; 4: 389-94.
19. WHITING P, RUTJES AW, REITSMA JB, et al.: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
20. ZHANG T, ZHONG W: Meta-DiSc Software in Meta-Analysis of Diagnostic Test. The Journal of Evidence-Based Medicine 2008; 8: 97-101.
21. CIPRIANI A, BARBUI C: What is a forest plot?. Epidemiol Psichiatr Soc 2006; 15: 258-9.
22. MIDGETTE AS, STUKEL TA, LITTENBERG B: A meta-analytic method for summarizing diagnostic test performances: receiver-operating- characteristic-summary point estimates. Med Decis Making 1993; 13: 253-7.
23. MOSES LE, SHAPIRO D, LITTENBERG B: Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993; 12: 1293-316.
24. HIGGINS JP, THOMPSON SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
25. PETITTI DB: Approaches to heterogeneity in meta-analysis. Stat Med 2001; 20: 3625-33.
26. NOLTING A, PERLETH M, LANGER G, et al.: [GRADE guidelines: 5. Rating the quality of evidence: publication bias] (In German). Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2012; 106: 670-6.
27. GAO IK, HAAS-WOHRLE A, MUELLER KG, et al.: Determination of anti-CCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist? Ann Rheum Dis 2005; 64: 1516-7.
28. ATES A, KARAASLAN Y, AKSARAY S: Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 2007; 26: 499-504.
29. LUIS CARO-OLEAS J, FERNANDEZ-SUAREZ A, RENESES CESTEROS S, et al.: Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent- onset polyarthritis. Clin Chem Lab Med 2007; 45: 1396-401.
30. ABDEL-NASSER AM, MAHMOUD MH, El MANSOURY TM, et al.: Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scand J Rheumatol 2008; 37: 329-36.
31. MOGHIMI J, GHORBANI R, HASANI F, et al.: Discriminative and diagnostic value of anticyclic citrullinated peptide antibodies in Iranian patients with rheumatoid arthritis. Rheumatology Int 2012; 33: 601-5.
32. BAS S, GENEVAY S, MEYER O, et al.: Anticyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 2003; 42: 677-80.
33. LEE DM, SCHUR PH: Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62: 870-4.
34. CHOI SW, LIM MK, SHIN DH, et al.: Diagnostic performances of anti-cyclic citrullinatedpeptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis. J Korean Med Sci 2005; 20: 473-8.
35. MU R, SUN XY, LI ZG: [Diagnostic significance of combined detection of rheumatoid factor and anticyclic citrullinated peptide antibodies in rheumatoid arthritis] (In Chinese). Beijing Da Xue Xue Bao 2005; 37: 498-500.
36. MATSUI T, SHIMADA K, OZAWA N, et al.: Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 2006; 33: 2390-7.
37. HEIDARI B, FIROUZJAHI A, HEIDARI P, et al.: The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis. Ann Saudi Med 2009; 29: 467-70
38. BIZZARO N, MAZZANTI G, TONUTTI E, et al.: Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089-93
39. VALLBRACHT I, RIEBER J, OPPERMANN M, et al.: Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1079-84
40. GREINER A, PLISCHKE H, KELLNER H, et al.: Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005; 1050: 295-303
41. KUDO-TANAKA E, OHSHIMA S, ISHII M, et al.: Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol 2007; 26: 1627-33
42. SILVEIRA IG, BURLINGAME RW, VON MUHLEN CA, et al.: Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 2007; 26: 1883-89
43. YAMANE T, HASHIRAMOTO A, TANAKA Y, et al.: Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor. J Rheumatol 2008; 35: 414-20
44. XIE QB, YIN G: [Predictive values of anticyclic citrullinated peptide antibody, antikeratin antibody and rheumatoid factor in diagnosing articular erosions in patients with rheumatoid arthritis] (In Chinese). Sichuan Da Xue Xue Bao Yi Xue Ban 2009; 40: 508-512
45. AFLAKY E, SHENAVANDEH S, ASHRAF MJ: A comparison of performance of anti-cyclic citrullinated peptide 2 and citrullinated protein antibodies in the diagnosis of rheumatoid arthritis in Iranian patients. Rheumatol Int 2010; 30:461-66
46. LIU X, JIA R, ZHAO J, et al.: The role of antimutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis. J Rheumatol 2009; 36:1136-42
47. Hodkinson B, Meyer PW, Musenge E, et al.: The diagnostic utility of the anti-CCP antibody test is no better than rheumatoid factor in South Africans with early rheumatoid arthritis. Clin Rheumatol 2010; 29:615-18
48. LIAO J, IP WS, CHEUNG KY, et al.: Diagnostic utility of an anti-CCP point-of-care immunotest in Chinese patients with rheumatoid arthritis. Clin Chem Acta 2011; 412: 778-81
49. HOU YF, SUN GZ, SUN HS, et al.: Diagnostic value of anti-Sa and anticitrullinated protein antibodies in rheumatoid arthritis. J Rheumatol 2012; 39: 1506-08
50. ZINTZARAS E, PAPATHANASIOU AA, ZIOGAS DC, et al.: The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates. BMC Musculoskelet Disord 2012; 13: 113
51. VAN VENROOIJ WJ, VAN BEERS JJ, PRUIJN GJ: Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 2008; 1143: 268-85
52. RUTJES AW, REITSMA JB, DI NISIO M, et al.: Evidence of bias and variation in diagnostic accuracy studies. CMAJ 2006; 174: 469-76.